The experience of transcatheter closure of postoperative ventricular septal defect after total correction

N’goran Yves N’da Kouakou¹, Jinyoung Song²*, June Huh² and I-Seok Kang²

Abstract

Background: The purpose of this study was to describe our experience with patients who underwent transcatheter closure of a post-operative ventricular septal defect (VSD).

Methods: All patients who underwent transcatheter closure of a VSD after total correction of congenital heart disease since 2012 were enrolled. Medical records were retrospectively reviewed to determine the patients’ initial diagnosis, closure device used, and final outcome after device closure.

Results: Six patients with a median age of 17.7 years (range: 7 months–48 years) underwent transcatheter closure of an unresolved VSD. The median time interval from the initial corrective surgery to the percutaneous closure procedure was 10.4 years (range: 0.3–33.0 years). The initial diagnoses included tetralogy of Fallot (one patient), VSD (two patients), double outlet of the right ventricle (two patients), and aortic valve stenosis (one patient). The reasons for unresolved VSD (other than leakage) after corrective surgery included previous fenestration (in two patients), and iatrogenic Gerbode shunt (in one patient). Various devices were used, including the Amplatzer duct occluder I, Amplatzer duct occluder II, Amplatzer vascular plug II, and Cocoon membranous VSD occluder. Only one device was used in each patient. There were no major complications associated with the closure procedures. The immediate results were satisfactory. The median follow-up duration was 2.75 years. All cases were successful, with the exception of minimal leak in one patient.

Conclusions: Transcatheter device closure of post-operative VSD can be performed using various device types and is safe and effective. But more experiences are mandatory.

Keywords: Catheterization, Heart septal defects, Ventricles, Postoperative

Background

Postoperative ventricular septal defect (VSD) is a relatively common finding after correction of an isolated VSD or complex cardiac anomalies. Postoperative VSD may arise due to patch dehiscence, suture disruption, incomplete closure of the defect, or bacterial endocarditis. The incidence of postoperative VSD varies according to the type of initial defect, and ranges from 5 to 25% [1]. Although some of these residual VSDs are restrictive and well tolerated, they may result in left-to-right shunting, persistent left ventricular volume overload, or pulmonary hypertension. Therefore, postoperative VSDs may require re-intervention [2]. Rarely, an iatrogenic VSD may form after surgery. VSD closure with fenestration is another cause of postoperative VSD. Surgical repair remains the mainstay of treatment for postoperative residual VSD. A repeat surgical repair procedure (involving cardiopulmonary bypass and sternotomy) is physically and psychologically traumatic for pediatric patients given the requirement for extracorporeal circulation and risks of myocardial scarring and bleeding [3]. Transcatheter closure of a post-operative VSD has emerged as a less invasive approach that can be used in selected patients to avoid the high morbidity and mortality associated with repeated surgical repair [4].

However, few studies have evaluated the transcatheter approach in the treatment of postoperative VSD [5, 6].

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Therefore, we reviewed our institutional experience with transcatheter closure of postoperative residual VSDs and report mid-term outcomes.

Methods
Six patients who underwent transcatheter closure of postoperative VSDs at Samsung Medical Center between January 2012 and December 2017 were enrolled. Patients’ medical records were reviewed retrospectively. Transthoracic echocardiography (TTE) was performed preoperatively to evaluate the VSD size and location, potential hemodynamic consequences, and any associated lesions prior to attempting a postoperative VSD repair. The indications for transcatheter closure of postoperative VSDs included a VSD with clinical evidence of volume overload, or pulmonary hypertension due to shunt. Device closure can be considered when the VSD is adequately separated in space from adjacent cardiac structures, including the aortic and tricuspid valves.

The procedure was performed under general anesthesia and using the guidance of transesophageal echocardiography (TEE). Patients received 100 IU/kg intravenous heparin immediately after the femoral artery was accessed. Continuous heparin infusion was maintained to reach an activated clotting time target of 200 msec. Following routine cardiac catheterization and hemodynamic evaluation, left ventricular angiographic images were obtained to determine the most appropriate device for closure.

Similar procedures were applied in every patient. The VSD was crossed in a retrograde fashion from the aorta using a 0.035” Terumo® guide wire, which was snared at the pulmonary artery and withdrawn through the femoral venous sheath (femoral arteriovenous loop). After ensuring that the tricuspid chordae had not been crossed, the catheter was advanced over the guide wire to the inferior vena cava. A long delivery sheath was passed over the guide wire from the femoral vein to the ascending aorta or left ventricle. The device was then attached to the delivery cable and passed through the delivery sheath. The distal disc was opened in the aorta or the left ventricle, and then the entire system was withdrawn. After confirming that the left ventricular disc was in the correct position, the other portion of the device was opened in the right ventricle. After verifying the position of the device using TEE and angiography, the device was released. We did not attempt any cases without the femoral arteriovenous loop.

After device implantation, a continuous intravenous heparin infusion was administered. Electrocardiographic monitoring was performed for 24 h after closure. If there were no complications, the patient was discharged 2 days later. Aspirin was prescribed at 3–5 mg/kg/day for 6 months following the procedure. A TTE was performed on the first postoperative day, and then regularly at 3, 6, and 12 months in the outpatient clinic.

The institutional review board approved this study. The need for informed consent was waived.

Results
VSD closure was performed successfully in all patients. Patient data are summarized in Table 1. The median age and body weight at the time of catheter closure were 17.7 years and 36.4 kg, respectively. The original diagnoses and surgeries were as follows: isolated VSD closure in two patients; tetralogy of Fallot (TOF) total correction; Fallot type double outlet of the right ventricle (DORV) total correction; Rastelli operation for DORV with coarctation; and Ross-Konno operation for congenital aortic stenosis. A systolic murmur was audible in all six patients. Pulmonary hypertension was observed in three patients. The reasons for postoperative VSD were residual shunt in three patients (Fig. 1a-d), fenestrated patch in two patients (Fig. 2a-c), and iatrogenic Gerbode shunt in one patient (Fig. 3a-c). The median time between surgery and percutaneous closure was 10.4 years (0.3–33.0 years).

We used one device for each patient. We used the following devices: Amplatzer duct occluder (ADO) I; ADO II; Amplatzer vascular plug (AVP) II; or a Cocoon membranous VSD occluder. The potential major complications associated with this procedure include death, device embolization, heart block, new valvular regurgitation, hemolysis requiring blood transfusion, or the need for surgical or percutaneous re-intervention. None of these complications arose in our patients. The immediate results were satisfactory. Small leaks were present in three patients. The median follow-up period was 2.8 years (3.0 months–4.8 years). All of the patients had successful results, except for one patient, who had a residual minimal leak.

Discussion
Although this study included a very small number of cases, we found that transcatheter closure of postoperative VSD can be performed safely and effectively using various devices. The postoperative VSDs in our series not only resulted from residual leaks, but also from fenestration and Gerbode shunt.

Patients 3 years old and over with hemodynamically significant perimembranous VSD that is adequately separated from the aortic and tricuspid valves are ideal candidates for a transcatheter approach. In cases of a muscular VSD, transcatheter closure is also considered suitable for children weighing ≥5 kg [7]. However, on review of the literature, we did not find any mention of transcatheter closure of postoperative VSDs. It is generally accepted that most postoperative VSDs can be safely
Table 1  Basic clinical characteristics of cases

|   | Sex | Weight (Kg) | Age of operation | Age of device closure | Original CHD/operation | Reasons of residual VSD | Closure indication | Device/size | Combined Procedure | Immediate leak | F/U period (year) | Last echo cardiac |
|---|-----|-------------|------------------|-----------------------|------------------------|------------------------|-------------------|------------|-------------------|----------------|-----------------|------------------|
| 1 | M   | 55.0        | 47 yr            | 48.7 yr               | TOF/total repair       | Fenestration           | Qp/Qs 1.9 Mean PA 38 mmHg | Cocoon VSD occlude membranous type/7.5 mm | Nothing | No              | 2.3            | No leak          |
| 2 | M   | 84.7        | 8yr              | 33 yr                 | PM VSD/closure         | Leakage                | Qp/Qs around 1.5       | ADO II/4–4 mm | Nothing | No              | 3.2            | No leak          |
| 3 | F   | 112         | 6mo              | 2.4 yr                | DORV (TOF type)/total repair | Iatrogenic (Gerbode shunt) | LV dilatation LPA stenosis | ADO V5–4 mm | LPA stent | Yes            | 4.4            | Small leak       |
| 4 | M   | 76.0        | 1mo              | 8mo                   | Congenital AS/Ross-Konno operation | Iatrogenic           | Elevated LV ENDP, moderate PS | AVP II/10 mm | PS balloon | No             | 4.8            | No leak          |
| 5 | F   | 53.2        | 10yr             | 43yr                  | MO VSD/closure         | Leakage                | Qp/Qs 1.5 Mean PA 26 mmHg | Cocoon VSD occlude membranous type/7.5 mm | Nothing | Yes            | 0.7            | No leak          |
| 6 | F   | 70.0        | 4mo              | 7mo                   | DORV (VSD type) CoA/ Norwood and Rastelli operation | Fenestration         | Cardiomegaly           | Cocoon VSD occlude membranous type/5.5 mm | Nothing | Yes            | 1.2            | No leak          |

F/U follow-up, TOF tetralogy of Fallot, Qp pulmonary flow, Qs systemic flow, PA pulmonary artery, PM perimembranous, VSD ventricular septal defect, ADO Amplatzer duct occluder, ORV double outlet right ventricular, LV left ventricle, LPA left pulmonary artery, AS aortic stenosis, LVENDP left ventricular end-diastolic pressure, PS pulmonary stenosis, AVP Amplatzer vascular plug, MO muscular outlet, Coa coarctation of the aorta.
closed using such a device. However, the location of the VSD, and the reasons for its development must be considered to identify good candidates for this type of closure. It is sometimes difficult to determine the precise location of postoperative VSDs. Therefore, a comprehensive understanding of the prior surgery is critical. For instance, if the post-operative VSD is located at the center of a patch of a previous VSD (that was closed with fenestration), the risk of aortic valve injury, tricuspid valve injury, or heart block should be minimal. Otherwise, the most important factor is the VSD’s distance from the aortic valve.

Most cases of postoperative VSD result from leakage following VSD closure. Most residual defects < 2 mm in size will close spontaneously, while those > 2 mm will not [7, 8]. Volume overload and infective endocarditis are two reasons that a postoperative VSD requires intervention. We described three patients with leakage of the VSD and evidence of volume overload who were successfully treated.

Fig. 1 Device closure of residual postoperative VSD with Coccoon VSD occlude device. a LV angiography showed residual VSD (black arrow). b Transesophageal echocardiography and color Doppler revealed residual VSD (white arrow) with significant amount. c LV angiography showed successful implantation of the Coccoon device (black arrow) with no significant leakage. d Transsthoracic echocardiography showed successful device closure after the procedure (white arrow). LV, left ventricle; AO, aorta; RV, right ventricle; VSD, ventricular septal defect.

Fig. 2 Device closure of VSD fenestration with Coccoon VSD occlude device. a Transthoracic echocardiography and color Doppler showed VSD through patch fenestration (white arrow). b Two dimensional echocardiography showed implanted Coccoon device successfully (white arrow). c A good device position (black arrow) and immediate minimal leakage was proven on LV angiography. LV, left ventricle; AO, aorta; RV, right ventricle; VSD, ventricular septal defect.
We also report one patient with a Gerbode defect involving a left ventricular to right atrial communication after DORV total correction. Acquired Gerbode shunts are thought to result from endocarditis, trauma, myocardial infarct, and as a complication of cardiac surgery [9, 10]. The percutaneous closure of Gerbode shunts has previously been described by Song et al. [11] Due to its proximity to the atrioventricular node and the tricuspid valve, close monitoring is necessary both during and after percutaneous closure of a Gerbode shunt.

Two patients in this study had residual VSDs due to fenestrated patch closures. In these circumstances, VSD closure is performed using a fenestrated or valved patch to reduce the risk of right heart decompensation [12, 13]. After postoperative stabilization and further interventional management of hypoplastic or stenotic pulmonary arteries, VSD closure may be necessary at a later date. Transcatheter closure of these VSDs remains challenging. It is particularly difficult due to the extremely flat anatomy of the patch material, and the short distance to the aortic valve [12].

Most patients had evidence of volume overload. However, it was difficult to measure Qp/Qs given the patients’ condition during the procedure. Two patients not only had postoperative VSD, but also pulmonary stenosis. We corrected the pulmonary stenosis and VSD simultaneously, because a VSD shunt might increase in intensity after relief of pulmonary stenosis alone. Therefore, postoperative VSDs should be evaluated in consideration of the patient’s overall cardiac condition.

We used various devices in the closure procedures. The Amplatzer muscular VSD occluders, perimembranous VSD occluders, ADOs, and septal occluders have previously been used to close VSDs percutaneously [14, 15]. We had good results when the postoperative VSD was closed using a cocoon membranous VSD occlude. There were no complications during follow-up in these cases. In general, several complications have been reported after percutaneous closure of a postoperative VSD. These include death, device embolization, heart block, new valvular regurgitation, hemolysis requiring blood transfusion, and the need for subsequent surgical or percutaneous interventions [1–4]. The most serious complication is complete atrioventricular block (cAVB), especially after transcatheter closure of a perimembranous VSD. The incidence of cAVB ranges 0–5.7% [1]. The occurrence of cAVB is related to proximity of the conduction system to the margins of the VSD. Fibrosis or scar formation can occur in the margins of the VSD after a previous operation. Therefore, we suspected that the abovementioned subsequent negative influence of the occluder might decrease, reducing the occurrence of cAVB after closure of postoperative residual VSD [4]. In addition, we used the femoral arteriovenous loop for all cases. However, in some cases, only the femoral vein or artery approach is possible. Therefore, it depends on the location of the VSD and the device. Devices with symmetric retention discs can be implanted through the femoral artery.

Based on our experience, we can recommend transcatheter closure of postoperative VSDs in patients with symptoms of failure. Most postoperative VSDs can be closed using various device types. Transcatheter closure can only be safely performed in patients > 7 kg. In particular, fenestrated VSDs can be safely and effectively closed if the fenestration is no longer necessary. However, surgical closure should be considered if combined lesion also requires surgical repair.

Our study has several limitations. This was a retrospective study based on a small series of cases from a single tertiary center. It also had a short follow-up period. Therefore, the study design itself may have introduced bias. We were unable to measure necessary objective data before and after the intervention, including the Qp/Qs and pulmonary pressures. Therefore, no definitive conclusions should be drawn from our findings.
Conclusion
Transcatheter closure of postoperative VSD was performed safely and effectively in our sample of patients. Transcatheter closure seems to be an effective alternative treatment option for postoperative VSD. Given the small number of participants in our study, further analysis is required to evaluate its long-term safety and efficacy.

Abbreviations
ADO: Amplatzer duct occlude; AVP: Amplatzer vascular plug; cAVB: Complete atrioventricular block; DORV: Double outlet of the right ventricle; TEE: Transesophageal echocardiography; TOF: Tetralogy of Fallot; TTE: Transthoracic echocardiography; VSD: Ventricular septal defect

Acknowledgements
Not applicable.

Authors’ contributions
NK analyzed the data and wrote the manuscript. JS was a major contributor to manuscript writing. JH and IK analyzed and interpreted the data. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
This study was approved by the ethics committee. Informed consent was waived.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cardiology, Institute Cardiology d’Abidjan, Abidjan, Côte d’Ivoire. 2Department of Pediatrics, Samsung Medical Center, Heart Vascular Stroke Institute, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.

Received: 12 April 2019 Accepted: 4 June 2019
Published online: 11 June 2019

References
1. Bol-Raap G, Weerheim J, Kappetein AP, Witsenburg M, Bogers AJ. Follow-up after surgical closure of congenital ventricular septal defect. Eur J Cardiothorac Surg. 2003;24:511–5.
2. Pedra CA, Pontes SC Jr, Pedra SR, Salerno L, Sousa JB, Maia MA, et al. Percutaneous closure of postoperative and post-traumatic ventricular septal defects. J Invasive Cardiol. 2007;19:491–5.
3. Yin S, Zhu D, Lin K, An Q. Percutaneous device closure of congenital ventricular septal defects. J Card Surg. 2014;29:390–400.
4. Egbe AC, Poterucha JT, Rihal CS, Taggart NW, Cetta F, Cabalka AK, et al. Transcatheter closure of postmyocardial infarction, iatrogenic, and postoperative ventricular septal defects: the Mayo Clinic experience. Catheter Cardiovasc Interv. 2015;86:1264–70.
5. Dua JS, Caminati M, Lucente M, Raza R, Chessa M, Negra D, et al. Transcatheter closure of postsurgical residual ventricular septal defects: early and mid-term results. Catheter Cardiovasc Interv. 2010;75:246–55.
6. Walsh MA, Coleman DM, Oslizlok P, Walsh KP. Percutaneous closure of postoperative ventricular septal defects with the Amplatzer device. Catheter Cardiovasc Interv. 2006;67:451–51 discussion 452.
7. Zhou W, Li F, Fu L, Gao W, Guo Y, Liu T, et al. Clinical experience of transcatheter closure for residual ventricular septal defect in pediatric patients. Congenit Heart Dis. 2016;11:323–31.
8. Dodge-Khatami A, Knirsch W, Tomasz M, Pietre R, Bettex D, Rousson V, et al. Spontaneous closure of small residual ventricular septal defects after surgical repair. Ann Thorac Surg. 2007;83:902–5.
9. Newman JN Jr, Rozanski L, Kreulen T. Acquired left ventricular to right atrial intracardiac shunt after myocardial infarction: a case report and review of the literature. J Am Soc Echocardiogr. 1996;9:716–20.
10. Gerbode F, Hultgren H, Méléro D, Osborn J. Syndrome of left ventricular-right atrial shunt; successful surgical repair of defect in five cases, with observation of bradyarrhythmia on closure. Ann Surg. 1958;148:433–46.
11. Lee SY, Song JY, Baek JS. Percutaneous closure of the acquired gerbode shunt using the amplatzer duct occluder in a 3-month old patient. Korean Circ J. 2013;43:429–31.
12. Haas NA, Kock L, Happel CM, Kececioglu D, Kanzits M, Laser KT. First in man closure of a fenestrated ventricular septal defect (VSD) with a new paravalvar leak device (Occlutech PLD). Int J Cardiol. 2015;201:137–46.
13. Leach C, Phillips A, Chisolm J, Hill S, Cheatham J, Winch P, et al. Pulmonary atresia with ventricular septal defect and multifocal pulmonary blood supply: does an intensive interventional approach improve the outcome? Congenit Heart Dis. 2012;7:111–21.
14. Ramakrishnan S, Saxena A, Choudhary SK. Residual VSD closure with an ADO II device in an infant. Congenit Heart Dis. 2011;6:e60–3.
15. Caminati M, Butera G, Chessa M, De Giovanni J, Fisher G, Gewillig M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European registry. Eur Heart J. 2007;28:2361–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.